Merck Zocor Switch Decision In The UK Is Imminent
This article was originally published in The Tan Sheet
Executive Summary
The UK's health authority reportedly will issue a decision "any day now" on a proposed switch of Merck's prescription Zocor (simvastatin) to "pharmacy status.
You may also be interested in...
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
J&J/Merck Seeking Zocor Switch In UK; Mevacor Still Lead U.S. Candidate
The overall benefit to risk ratio for making Zocor (simvastatin) available without a prescription in the UK is "regarded as favorable," according to a consultation document issued Nov. 17 by the British health agency